AIM ImmunoTech Inc. announced progress in its clinical development of Ampligen® (rintatolimod), particularly in addressing critical unmet medical needs in areas like pancreatic cancer and Long-COVID.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback